References
- Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004. Pediatrics117, 1680–1687 (2006).
- Cotten CM, McDonald S, Stoll B et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics118, 717–722 (2006).
- Stoll BJ, Hansen NI, Adams-Chapman I et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA292, 2357–2365 (2004).
- Benjamin DK Jr, Stoll BJ, Fanaroff AA et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics117, 84–92 (2006).
- Kaufman D, Boyle R, Hazen KC et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med.345, 1660–1666 (2001).
- Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics107, 293–298 (2001).
- Kaufman D, Boyle R, Hazen KC et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J. Pediatr.147, 172–179 (2005).
- Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J. Pediatr.147, 166–171 (2005).
- Bertini G, Perugi S, Dani C et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J. Pediatr.147, 162–165 (2005).
- Manzoni P, Stolfi I, Pugni L et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N. Engl. J. Med.356, 2483–2495 (2007).
- Manzoni P, Arisio R, Mostert M et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics117, e22–e32 (2006).
- Uko S, Soghier LM, Vega M et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics117, 1243–1252 (2006).
- Aghai ZH, Mudduluru M, Nakhla TA et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J. Perinatol.26, 550–555 (2006).
- Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics121, 703–710 (2008).
- Weitkamp JH, Ozdas A, Lafleur B, Potts AL. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J. Perinatol.28(6), 405–411 (2008).
- Smith PB, Morgan J, Benjamin JD et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr. Infect. Dis. J.26, 197–200 (2007).
- Zaoutis TE, Heydon K, Localio R, Walsh TJ, Feudtner C. Outcomes attributable to neonatal candidiasis. Clin. Infect. Dis.44, 1187–1193 (2007).
- Procianoy RS, Eneas MV, Silveira RC. Empiric guidelines for treatment of Candida infection in high-risk neonates. Eur. J. Pediatr.165, 422–423 (2006).
- Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics109, 34–39 (2002).
- Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch. Dis. Child. Fetal Neonatal Ed.91, F188–F192 (2006).
- Clerihew L, Austin N, McGuire W. Systemic antifungal prophylaxis for very low birthweight infants: a systematic review. Arch. Dis. Child Fetal Neonatal Ed.93, F198–F200 (2008).
- Johnsson H, Ewald U. The rate of candidaemia in preterm infants born at a gestational age of 23–28 weeks is inversely correlated to gestational age. Acta Paediatr.93, 954–958 (2004).
- Makhoul IR, Bental Y, Weisbrod M et al.Candida versus bacterial late-onset sepsis in very low birthweight infants in Israel: a national survey. J. Hosp. Infect.65, 237–243 (2007).
- Hack M. Neonatology fellowship training in research pertaining to development and follow-up. J. Perinatol.26(Suppl. 2), S30–S33 (2006).
- Kramer MS, Platt RW, Wen SW et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics108, E35 (2001).
- Clancy CJ, Staley B, Nguyen MH. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob. Agents Chemother.50, 3496–3498 (2006).
- Kaufman DA, Manzoni P, Gurka MJ, Grossman LB. Antifungal prophylaxis in the neonatal intensive care unit (NICU). Curr. Pediatr. Rev.277–288 (2007).
- White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev.11, 382–402 (1998).
- Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?. Drug Resist. Updat.11(1–2), 25–31 (2008).
- Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood96, 2055–2061 (2000).
- Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis.181, 309–316 (2000).
- Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis.38, 161–189 (2004).
- Sobel JD, Wiesenfeld HC, Martens M et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N. Engl. J. Med.351, 876–883 (2004).
- Manzoni P, Mostert M, Latino MA et al. Routinary use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr. Infect. Dis. J. (2008) (In Press).
- Sarvikivi E, Lyytikainen O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J. Clin. Microbiol.43, 2729–2735 (2005).
- Yoder BA, Sutton DA, Winter V, Coalson JJ. Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model. Pediatr. Infect. Dis. J.23, 687–688 (2004).
- Parikh TB, Nanavati RN, Patankar CV et al. Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr.44, 830–837 (2007).
- Kaufman D, Boyle R, Robinson M, Grossman LB. Long-term safety of intravenous prophylactic fluconazole use in preterm infants less than 1000 grams. [abstract]. Pediatr. Res.53, 484A (2003).
- Sims ME, Yoo Y, You H, Salminen C, Walther FJ. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am. J. Perinatol.5, 33–36 (1988).
- Ozturk MA, Gunes T, Koklu E, Cetin N, Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses49, 484–492 (2006).
- Leibovitz E, Iuster-Reicher A, Amitai M, Mogilner B. Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin. Infect. Dis.14, 485–491 (1992).
- Weitkamp JH, Poets CF, Sievers R et al.Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection26, 11–15 (1998).
- El Masry FA, Neal TJ, Subhedar NV. Risk factors for invasive fungal infection in neonates. Acta Paediatr.91, 198–202 (2002).
- Johnson DE, Thompson TR, Green TP, Ferrieri P. Systemic candidiasis in very low-birth-weight infants (less than 1,500 grams). Pediatrics73, 138–143 (1984).
- Burwell LA, Kaufman D, Blakely J, Stoll BJ, Fridkin SK. Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics118, e1019–e1026 (2006).
- Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst. Rev.CD003850 (2007).
- Manzoni P, Stolfi I, Pugni L et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N. Engl. J. Med.356, 2483–2495 (2007).
- Candidiasis. In: Red Book: 2006 Report of the Committee on Infectious Diseases. Pickering L, Baker CJ, Long SS, McMillian JA (Eds). American Academy of Pediatrics, Elk Grove Village, IL, USA 246. (2006).